![PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells](https://www.researchgate.net/profile/Callinice-Capo-Chichi/publication/326786450/figure/fig1/AS:655308154208256@1533249047654/SBHA-induces-the-expression-of-endogenous-lamin-A-in-T47D-and-in-MCF7-transfected_Q320.jpg)
PDF) Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/4f5b7e28-6c4c-4bb6-95af-053ea2c836bf/bjh12384-fig-0002-m.jpg)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library
![PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma](https://i1.rgstatic.net/publication/256100894_MEF2B_mutations_lead_to_deregulated_expression_of_the_BCL6_oncogene_in_Diffuse_Large_B_cell_Lymphoma/links/0deec53c530523cce0000000/largepreview.png)
PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma
![PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells](https://www.researchgate.net/publication/338086934/figure/fig4/AS:838355818405889@1576891011949/17f-inhibits-STAT5B-N642H-activity-and-expression-in-Ba-F3-cells-A-Cells-were-treated_Q320.jpg)
PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/5a636b6e-588f-4e0b-befe-b0554820b177/bjh.2013.162.issue-3.cover.jpg)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cae3bb1d-3b59-4765-b8cf-cd18eb28a9b9/bjh12384-fig-0003-m.jpg)